180 related articles for article (PubMed ID: 37926711)
1. Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy.
Kim J; Koh DI; Lee M; Park YS; Hong SW; Shin JS; Lee MS; Kim MH; Lee JH; Jeong J; Bae S; Hong JK; Jeong HR; Ryu YS; Kim SM; Choi M; Kim H; Ryu H; Hur SC; Park J; Hur DY; Jin DH
Cell Death Differ; 2023 Dec; 30(12):2491-2507. PubMed ID: 37926711
[TBL] [Abstract][Full Text] [Related]
2. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
[TBL] [Abstract][Full Text] [Related]
3. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
Lu Y; Yao HP; Wang MH
Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
[TBL] [Abstract][Full Text] [Related]
4. Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
Krishnaswamy S; Mohammed AK; Tripathi G; Alokail MS; Al-Daghri NM
BMC Cancer; 2017 Nov; 17(1):738. PubMed ID: 29121914
[TBL] [Abstract][Full Text] [Related]
5. Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Int J Clin Exp Med; 2015; 8(11):20778-86. PubMed ID: 26885001
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
7. Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines.
Krishnaswamy S; Bukhari I; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Gene; 2018 Dec; 679():335-340. PubMed ID: 30223007
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
[TBL] [Abstract][Full Text] [Related]
9. Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer.
Yu H; Yuan J; Xiao C; Qin Y
Int J Mol Med; 2013 May; 31(5):1248-54. PubMed ID: 23483216
[TBL] [Abstract][Full Text] [Related]
10. Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/β-catenin pathway activation in a mouse model.
Lu T; Wang Z; Prativa S; Xu Y; Wang T; Zhang Y; Yu L; Xu N; Tang J; You W; Chen G; Zhang JH
J Neurochem; 2019 Jan; 148(1):114-126. PubMed ID: 30380151
[TBL] [Abstract][Full Text] [Related]
11. Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer.
Liu YZ; Han DT; Shi DR; Hong B; Qian Y; Wu ZG; Yao SH; Tang TM; Wang MH; Xu XM; Yao HP
World J Gastrointest Oncol; 2020 Nov; 12(11):1216-1236. PubMed ID: 33250957
[TBL] [Abstract][Full Text] [Related]
12. Involvement of recepteur d'origine nantais receptor tyrosine kinase in Epstein-Barr virus-associated nasopharyngeal carcinoma and its metastasis.
Chou YC; Chen CL; Yeh TH; Lin SJ; Chen MR; Doong SL; Lu J; Tsai CH
Am J Pathol; 2012 Nov; 181(5):1773-81. PubMed ID: 22974584
[TBL] [Abstract][Full Text] [Related]
13. The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
Millar R; Kilbey A; Remak SJ; Severson TM; Dhayade S; Sandilands E; Foster K; Bryant DM; Blyth K; Coffelt SB
Mol Oncol; 2020 Aug; 14(8):1868-1880. PubMed ID: 32484599
[TBL] [Abstract][Full Text] [Related]
14. RON alternative splicing regulation in primary ovarian cancer.
Mayer S; Hirschfeld M; Jaeger M; Pies S; Iborra S; Erbes T; Stickeler E
Oncol Rep; 2015 Jul; 34(1):423-30. PubMed ID: 25997828
[TBL] [Abstract][Full Text] [Related]
15. RON Receptor Tyrosine Kinase Regulates Epithelial Mesenchymal Transition and the Expression of Pro-Fibrotic Markers via Src/Smad Signaling in HK-2 and NRK49F Cells.
Park JS; Choi HI; Kim DH; Kim CS; Bae EH; Ma SK; Kim SW
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31690042
[TBL] [Abstract][Full Text] [Related]
16. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.
Wang MH; Yao HP; Zhou YQ
Acta Pharmacol Sin; 2006 Jun; 27(6):641-50. PubMed ID: 16723080
[TBL] [Abstract][Full Text] [Related]
17. Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression.
Beauvais DM; Nelson SE; Adams KM; Stueven NA; Jung O; Rapraeger AC
J Biol Chem; 2022 Jun; 298(6):102029. PubMed ID: 35569509
[TBL] [Abstract][Full Text] [Related]
18. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais.
Chen YQ; Zhou YQ; Fu LH; Wang D; Wang MH
Carcinogenesis; 2002 Nov; 23(11):1811-9. PubMed ID: 12419829
[TBL] [Abstract][Full Text] [Related]
19. Effect of Recepteur d'Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer.
Kim N; Cho SB; Park YL; Park SY; Myung E; Kim SH; Yu HM; Son YA; Myung DS; Lee WS; Joo YE
Oncol Rep; 2016 Jun; 35(6):3331-40. PubMed ID: 27035413
[TBL] [Abstract][Full Text] [Related]
20. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.
Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C
Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
